Charles River Laboratories International, Inc.CRLNYSE
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank62
3Y CAGR-13.3%
5Y CAGR-13.2%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-13.3%/yr
Quarterly compound
5Y CAGR
-13.2%/yr
Consistent
Percentile
P62
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 5.66% |
| Q3 2025 | -7.29% |
| Q2 2025 | 7.73% |
| Q1 2025 | -9.15% |
| Q4 2024 | -1.76% |
| Q3 2024 | 17.33% |
| Q2 2024 | -8.86% |
| Q1 2024 | -5.50% |
| Q4 2023 | 11.94% |
| Q3 2023 | -11.84% |
| Q3 2023 | 14.25% |
| Q2 2023 | -12.42% |
| Q4 2022 | 8.67% |
| Q3 2022 | 39.48% |
| Q2 2022 | -12.21% |
| Q1 2022 | 4.11% |
| Q4 2021 | -3.00% |
| Q3 2021 | -13.37% |
| Q2 2021 | 10.13% |
| Q1 2021 | 8.88% |
| Q4 2020 | 11.49% |
| Q3 2020 | 0.45% |
| Q2 2020 | -1.69% |
| Q1 2020 | 0.23% |
| Q4 2019 | 0.07% |
| Q3 2019 | -4.73% |
| Q2 2019 | 10.91% |
| Q1 2019 | 14.64% |
| Q4 2018 | -5.41% |
| Q3 2018 | -6.22% |
| Q2 2018 | 16.60% |
| Q1 2018 | 9.32% |
| Q4 2017 | 2.31% |
| Q3 2017 | -1.48% |
| Q3 2017 | 3.20% |
| Q2 2017 | -7.69% |
| Q4 2016 | 14.98% |
| Q3 2016 | -14.75% |
| Q2 2016 | 21.13% |
| Q1 2016 | 1.82% |